ArticleInternational journal of nanomedicine2010
Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies.
Article in International journal of nanomedicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 68 citations in OpenAlex.
- A review: hemocompatibility of magnetic nanoparticles and their regenerative medicine, cancer therapy, drug delivery, and bioimaging applications.Frontiers in chemistry · 2023Review
- Tissue Distribution, Histopathological and Genotoxic Effects of Magnetite Nanoparticles on Ehrlich Solid Carcinoma.Biological trace element research · 2022Article
- Application of nanotechnology in the early diagnosis and comprehensive treatment of gastrointestinal cancer.Journal of nanobiotechnology · 2022Review
- Toxicological Aspects of Iron Oxide Nanoparticles.Advances in experimental medicine and biology · 2022Article
- Current role of nanoparticles in the treatment of lung cancer.Journal of clinical and translational research · 2021Review
- Nanoparticles: A Hope for the Treatment of Inflammation in CNS.Frontiers in pharmacology · 2021Review
- Quantification of Synergistic Effects of Ceragenin CSA-131 Combined with Iron Oxide Magnetic Nanoparticles Against Cancer Cells.International journal of nanomedicine · 2020Article
- Iron Oxide Nanoparticles for Biomedical Applications: A Perspective on Synthesis, Drugs, Antimicrobial Activity, and Toxicity.Antibiotics (Basel, Switzerland) · 2018Review
- Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems.Pharmaceutics · 2017Review
- Fabrication and Cytotoxicity of Gemcitabine-Functionalized Magnetite Nanoparticles.Molecules (Basel, Switzerland) · 2017Article
- Article
- In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles.Chemical Society reviews · 2015Review
- Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles.Journal of nanobiotechnology · 2015Article
- Apoptosis selectively induced in BEL-7402 cells by folic acid-modified magnetic nanoparticles combined with 100 Hz magnetic field.International journal of nanomedicine · 2014Article
- Magnetite nanoparticles inhibit tumor growth and upregulate the expression of p53/p16 in Ehrlich solid carcinoma bearing mice.PloS one · 2014Article
- Article
- Gambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1.International journal of nanomedicine · 2012Article
- Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells.International journal of nanomedicine · 2012Article
- Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes.International journal of nanomedicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe objectives of this research were to assess the biocompatibility of self-assembled Fe(3)O(4) magnetic nanoparticles (MNPs) loaded with daunorubicin (DNR), ie, (Fe(3)O(4)-MNPs/DNR), and to explore their potential application in the treatment of hematologic malignancies.
methodsA hemolysis test was carried out to estimate the hematologic toxicity of Fe(3)O(4)- MNPs/DNR and a micronucleus assay was undertaken to identify its genotoxicity. Fe(3)O(4)-MNPs/ DNR were injected intraperitoneally into mice to calculate the median lethal dose (LD(50)). The general condition of the mice was recorded, along with testing for acute toxicity to the liver and kidneys.
resultsHemolysis rates were 2.908%, 2.530%, and 2.415% after treatment with different concentrations of Fe(3)O(4)-MNPs/DNR. In the micronucleus assay, there was no significant difference in micronucleus formation rate between the experimental Fe(3)O(4)-MNPs/DNR groups and negative controls (P > 0.05), but there was a significant difference between the experimental groups and the positive controls (P < 0.05). The LD(50) of the Fe(3)O(4)-MNPs/DNR was 1009.71 mg/kg and the 95% confidence interval (CI) was 769.11-1262.40 mg/kg, while that of the DNR groups was 8.51 mg/kg (95% CI: 6.48-10.37 mg/kg), suggesting that these nanoparticles have a wide safety margin. Acute toxicity testing showed no significant difference in body weight between the treatment groups at 24, 48, and 72 hours after intraperitoneal injection. The mice were all in good condition, with normal consumption of water and food, and their stools were formed and yellowish-brown. Interestingly, no toxic reactions, including instability of gait, convulsion, paralysis, and respiratory depression, were observed. Furthermore, alanine transaminase, blood urea nitrogen, and creatinine clearance in the experimental Fe(3)O(4)-MNPs/ DNR groups were 66.0 ± 28.55 U/L, 9.06 ± 1.05 mmol/L, and 18.03 ± 1.84 μmol/L, respectively, which was not significantly different compared with the control and isodose DNR groups.
conclusionSelf-assembled Fe(3)O(4)-MNPs/DNR appear to be highly biocompatible and safe nanoparticles, and may be suitable for further application in the treatment of hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.